136 related articles for article (PubMed ID: 37172367)
1. Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis.
Wu Q; Wang Q; Yang J; Mills EA; Chilukuri P; Saad A; Dowling CA; Fisher C; Kirch B; Mao-Draayer Y
Mult Scler Relat Disord; 2023 Jul; 75():104719. PubMed ID: 37172367
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
3. Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.
Canto-Gomes J; Silva CS; Rb-Silva R; Boleixa D; da Silva AM; Cheynier R; Costa P; González-Suárez I; Correia-Neves M; Cerqueira JJ; Nobrega C
Front Immunol; 2022; 13():901165. PubMed ID: 35711452
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
6. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis.
Canto-Gomes J; Boleixa D; Teixeira C; Martins da Silva A; González-Suárez I; Cerqueira J; Correia-Neves M; Nobrega C
Int Immunopharmacol; 2024 Apr; 131():111826. PubMed ID: 38461632
[TBL] [Abstract][Full Text] [Related]
7. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study.
Lycke J; Farman H; Nordin A
CNS Drugs; 2023 Feb; 37(2):181-188. PubMed ID: 36729276
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients.
Medina S; Sainz de la Maza S; Villarrubia N; Álvarez-Lafuente R; Costa-Frossard L; Arroyo R; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
Ann Clin Transl Neurol; 2019 Feb; 6(2):355-363. PubMed ID: 30847367
[TBL] [Abstract][Full Text] [Related]
10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide treatment reduces B cells in patients with MS.
Gandoglia I; Ivaldi F; Laroni A; Benvenuto F; Solaro C; Mancardi G; Kerlero de Rosbo N; Uccelli A
Neurol Neuroimmunol Neuroinflamm; 2017 Nov; 4(6):e403. PubMed ID: 29082295
[TBL] [Abstract][Full Text] [Related]
12. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
[TBL] [Abstract][Full Text] [Related]
14. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
15. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
Lazzaro C; Bergamaschi R; Zaffaroni M; Totaro R; Paolicelli D
Neurol Sci; 2022 Aug; 43(8):4933-4944. PubMed ID: 35420360
[TBL] [Abstract][Full Text] [Related]
17. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
18. Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.
D'Amico E; Zanghì A; Parrinello NL; Romano A; Palumbo GA; Chisari CG; Toscano S; Raimondo FD; Zappia M; Patti F
Front Immunol; 2022; 13():819136. PubMed ID: 35273601
[TBL] [Abstract][Full Text] [Related]
19. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
[TBL] [Abstract][Full Text] [Related]
20. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S; Ponzano M; Ivaldi F; Signori A; Lapucci C; Casella V; Ferrò MT; Vigo T; Inglese M; Mancardi GL; Uccelli A; Laroni A
CNS Drugs; 2022 Jan; 36(1):83-96. PubMed ID: 34894339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]